Phase 3
Completed N=372
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
Source: ClinicalTrials.gov NCT01171976 ↗Enrolled (actual)
372
Serious AEs
24.1%
Results posted
Sep 2014
Primary outcomePrimary: Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12 — 62.3; 64.1; 65.1; 68.25 Letters
Summary
The purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (PRN=as needed) treatment regimen.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12 |
62.3; 64.1; 65.1; 68.25; 70.28; 71.32 | — |
| SECONDARY Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 24 |
62.3; 64.1; 65.1; 69.12; 70.72; 72.09 | — |
| SECONDARY Visual Acuity of the Study Eye: Change From Baseline at Month 12 |
62.3; 65.1; 65.1; 69.13; 70.93; 72.56 | — |
| SECONDARY Visual Acuity of the Study Eye: Change From Baseline at Month 24 |
62.3; 64.1; 65.1; 70.64; 70.62; 73.18 | — |
| SECONDARY Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 12 |
82.9; 84.8; 83.8; 59.0; 60.8; 70.1 | — |
| SECONDARY Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 24 |
87.2; 84.0; 90.6; 69.2; 62.4; 76.1 | — |
| SECONDARY Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 12 |
-27.09; -24.35; -23.16 | — |
| SECONDARY Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 24 |
-32.03; -24.98; -24.97 | — |
| SECONDARY Visual Functioning Questionnaire (VFQ-25) Change From Baseline in Total Score at Month 12 and Month 24 |
75.32; 75.47; 77.07; 4.60; 3.95; 5.41 | — |
| SECONDARY EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24 |
71.4; 70.7; 72.2; 0.47; 0.91; 2.52 | — |
Eligibility Criteria
Inclusion Criteria
Patient
- Patients with Type 1 or Type 2 diabetes mellitus (according to American Diabetes Association or World Health Organization [WHO] guidelines) with glycosylated hemoglobin (HbA1c) ≤ 12.0% at screening (Visit 1). Patients should be on diet, exercise, and/or pharmacological treatment for diabetes. Treatment for diabetes must have been stable for at least 3 month.
Ocular
- Patients with visual impairment due to DME in at least one eye who are eligible for laser treatment in the opinion of the investigator. If both eyes are eligible, the one with the worse visual acuity, as assessed at Visit 1, will be selected by the investigator as the study eye.
- BCVA ≥ 39 and ≤78 letters in the study eye and, inclusively, using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160) at screening.
- Concomitant conditions in the study eye are only permitted if, in the opinion of the investigator, they do not prevent improvement of visual acuity on study treatment.
Exclusion Criteria
Patient Compliance/ Administrative
- Pregnant or nursing (lactating) women.
Ocular medical history
- Active intraocular inflammation (grade trace or above) in either eye at enrollment.
- Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye at the time of enrollment.
- History of uveitis in either eye at any time.
- Structural damage within 0.5 disc diameter of the center of the macular in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema.
- Uncontrolled glaucoma in either eye at screening.
Prior Ocular treatments
- Panretinal laser photocoagulation in the study eye within 6 months prior to randomization.
- Focal/grid laser photocoagulation in the study eye within 3 months prior to randomization.
- Treatment with anti-angiogenic drugs in either eye.
Systemic conditions or treatments
- History of stroke within 6 months prior to enrollment.
- Renal failure requiring dialysis.
- Untreated diabetes mellitus.
- Blood pressure systolic > 160 mmHg or diastolic > 100 mmHg.
Other protocol-defined inclusion/exclusion criteria may apply
Data sourced from ClinicalTrials.gov (NCT01171976). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.